Circulating fibroblast growth factor-23 plasma levels predict adverse cardiovascular outcomes in patients with diabetes mellitus with coronary artery disease

Diabetes/Metabolism Research and Reviews

Volumn 32, Issue 7, 2016, Pages 685-693

  Tuñón, José ^a,b   Fernández Fernández, Beatriz ^a   Carda, Rocío ^a   Pello, Ana M ^a   Cristóbal, Carmen ^c,d   Tarín, Nieves ^e   Aceña, Álvaro ^a   González Casaus, María Luisa ^f   Huelmos, Ana ^g   Alonso, Joaquín ^d,h   Lorenzo, Óscar ^a,b   González Parra, Emilio ^a,b   Hernández González, Ignacio ^a   Mahíllo Fernández, Ignacio ^a   López Bescós, Lorenzo ^d   Egido, Jesús ^a,b,i  

^a 28400 Madrid   (Spain)

^b UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO DE FUENLABRADA   (Spain)

^d UNIVERSIDAD REY JUAN CARLOS   (Spain)

^e HOSPITAL DE MÓSTOLES   (Spain)

^f HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

^g HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^h HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

coronary artery disease; diabetes mellitus; fibroblast growth factor 23; mineral metabolism; vitamin D

Indexed keywords

CALCIDIOL; CALCIDIOL 1 MONOOXYGENASE; FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BONE METABOLISM; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

EID: 84989948152     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.2787     Document Type: Article

References (38)

1. Scialla JJ, Wolf M. Roles of phosphate and fibroblast growth factor 23 in cardiovascular disease. Nat Rev Nephrol 2014; 10: 268–278.
2. Gonzalez-Parra E, Rojas-Rivera J, Tuñón J, Praga M, Ortiz A, Egido J. Vitamin D receptor activation and cardiovascular disease. Nephrol Dial Transplant 2012; 27(Suppl4): iv17–21.
3. Gonzalez-Parra E, Tuñón J, Egido J, Ortiz A. Phosphate: a stealthier killer than previously thought? Cardiovasc Pathol 2012; 21: 372–381.
4. Tuñón J, Cristóbal C, Tarín N, et al. Coexistence of low vitamin D and high fibroblast growth factor-23 plasma levels predicts an adverse outcome in patients with coronary artery disease. PLoS One 2014; 9 e95402.
5. Wolf M. Forging forward with 10 burning questions on FGF-23 in kidney disease. J Am Soc Nephrol 2010; 21: 1427–1435.
6. Nitta K, Nagano N, Tsuchiya K. Fibroblast growth factor 23/klotho axis in chronic kidney disease. Nephron Clin Pract 2014; 128: 1–10.
7. Agarwal R, Duffin KL, Laska DA, Voelker JR, Breyer MD, Mitchell PG. A prospective study of multiple protein biomarkers to predict progression in diabetic chronic kidney disease. Nephrol Dial Transplant 2014; 29: 2293–2302.
8. Wang L, Song Y, Manson JE, et al. Circulating 25-hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective studies. Circ Cardiovasc Qual Outcomes 2012 Nov;5(6): 819–29. doi: http://dx.doi.org/10.1161/CIRCOUTCOMES.112.967604.
9. Brøndum-Jacobsen P, Benn M, Jensen GB, Nordestgaard BG. 25-hydroxyvitamin d levels and risk of ischemic heart disease, myocardial infarction, and early death: population-based study and meta-analyses of 18 and 17 studies. Arterioscler Thromb Vasc Biol 2012; 32: 2794–2802.
10. Faul C, Amaral AP, Oskouei B, et al. FGF-23 induces left ventricular hypertrophy. J Clin Invest 2011; 121: 4393–4408.
11. Kestenbaum B, Katz R, de Boer I, et al. Vitamin D, parathyroid hormone, and cardiovascular events among older adults. J Am Coll Cardiol 2011; 58: 1433–1441.
12. van Ballegooijen AJ, Snijder MB, Visser M, et al. Vitamin D in relation to myocardial structure and function after eight years of follow-up: the Hoorn study. Ann Nutr Metab 2012; 60: 69–77.
13. Taylor EN, Curhan GC, Forman JP. Parathyroid hormone and the risk of incident hypertension. J Hypertens 2008; 26: 1390–1394.
14. Anderson JL, Vanwoerkom RC, Horne BD, et al. Parathyroid hormone, vitamin D, renal dysfunction, and cardiovascular disease: dependent or independent risk factors? Am Heart J 2011; 162: 331–339.
15. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054–2060.
16. Hagström E, Hellman P, Larsson TE, et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation 2009; 119: 2765–2771.
17. Wang TJ, Pencina MJ, Booth SL, et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117: 503–511.
18. Tastan I, Schreckenberg R, Mufti S, Abdallah Y, PiperHM SKD. Parathyroid hormone improves contractile performance of adult rat ventricular cardiomyocytes at low concentrations in a non-acute way. Cardiovasc Res 2009; 82: 77–83.
19. Aceña A, Pello A, Carda R, et al. Parathormone levels are independently associated with the presence of left ventricular hypertrophy in patients with coronary artery disease. J Nutr Health and Aging 2016; in press
20. Yoda K, Imanishi Y, Yoda M, et al. Impaired response of FGF-23 to oral phosphate in patients with type 2 diabetes: a possible mechanism of atherosclerosis. J Clin Endocrinol Metab 2012; 97: E2036–E2043.
21. Levey AS, Stevens LA, Schmid CH, et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150: 604–612.
22. Summary of recommendation statements. Kidney Intern Suppl 2013; 3: 5–14. doi:http://dx.doi.org/10.1038/kisup.2012.77.
23. Mirza MA, Larsson A, Lind L, Larsson TE. Circulating FGF-23 is associated with vascular dysfunction in the community. Atherosclerosis 2009; 205: 385–390.
24. Mirza MA, Hansen T, Johansson L, et al. Relationship between circulating FGF-23 and total body atherosclerosis in the community. Nephrol Dial Transplant 2009; 24: 3125–3131.
25. Ärnlöv J, Carlsson AC, Sundström J, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013; 83: 160–166.
26. Nasrallah MM, El-Shehaby AR, Salem MM, et al. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant 2010; 25: 2679–2685.
27. Sharma S, Joseph J, Chonchol M, et al., Investigators HOST. Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients. Clin Nephrol 2013; 80: 313–321.
28. Masai H, Joki N, Sugi K, Moroi M. A preliminary study of the potential role of FGF-23 in coronary calcification in patients with suspected coronary artery disease. Atherosclerosis 2013; 226: 228–233.
29. Gutiérrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008; 359: 584–592.
30. di Giuseppe R, Buijsse B, Hirche F, et al. Plasma fibroblast growth factor 23, parathyroid hormone, 25-hydroxyvitamin D3, and risk of heart failure: a prospective, case-cohort study. J Clin Endocrinol Metab 2014; 99: 947–955.
31. Pello AM, Cristóbal C, Tarín N, et al. Differential profile in inflammatory and mineral metabolism biomarkers in patients with ischemic heart disease without classical coronary risk factors. J Cardiol 2015; 66: 22–27.
32. Scialla JJ, Xie H, Rahman M, et al. Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor-23 and cardiovascular events in CKD. J Am Soc Nephrol 2014; 25: 349–360.
33. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152: 640–648.
34. Hanks LJ, Casazza K, Judd SE, Jenny NS, Gutiérrez OM. Associations of fibroblast growth factor-23 with markers of inflammation, insulin resistance and obesity in adults. PLoS One 2015; 10(3e0122885).
35. Nakano C, Hamano T, Fujii N, et al. Combined use of vitamin D status and FGF-23 for risk stratification of renal outcome. Clin J Am Soc Nephrol 2012; 7: 810–819.
36. Kidney Disease: Improving Global Outcomes (KDIGO) CKD–MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD–MBD). Kidney Intern 2009; 76(Suppl 113): S1–S130.v.
37. Barter PJ, Caulfield M, Eriksson M, et al, Investigators ILLUMINATE. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109–2122.
38. Morgantini C, Meriwether D, Baldi S, et al. HDL lipid composition is profoundly altered in patients with type 2 diabetes and atherosclerotic vascular disease. Nutr Metab Cardiovasc Dis 2014; 24: 594–599.